Chronic axial pain history was indicated in about 25% of patients with inflammatory bowel disease.
In healthy women with normal ovulatory function, treatment with elagolix suppressed ovulation in a dose-dependent manner and reduced endometrial thickness at doses used to treat endometriosis pain.
The Food and Drug Administration (FDA) has approved the Senza Omnia Spinal Cord Stimulation (SCS) System (Nevro) for the treatment of chronic intractable pain of the trunk and/or limbs.
Between 2005 and 2015, there was a more than twofold increase in the percentage of adults with cancer using gabapentinoids.
Researchers found that overall research design and methodological criteria need to be examined closely to gauge true treatment effects in chronic pain clinical trials.
Researchers conducting a comprehensive literature review for painful Hashimoto thyroiditis identified only 70 cases of the rare condition.
By reducing the burden of pain and opioid use in patients with chronic, intractable pain, 10 kHz spinal cord stimulation has the potential to reduce the health care costs associated with these patients’ care.
Young adult women who experienced child maltreatment are at higher risk for pain.
Changes in pain sensitization and depressive symptoms may partially mediate reduction in knee pain after substantial weight loss in morbidly obese individuals with knee pain.
Patients with new-onset low back pain who initially consulted a chiropractor or physical therapist vs a primary care physician were found to have reduced risk for long-term opioid use.